SCHEMBL21777129

SCHEMBL21777129

NS(=O)(=O)c1ncccc1-c1cscn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.45
TDO2 P48775 3/20 0.45
CASP6 P55212 1/20 0.41
CA1 P00915 7/20 0.39
CA2 P00918 7/20 0.39
CA9 Q16790 4/20 0.39
CA12 O43570 3/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
MAPK1 P28482 1/20 0.35
KDM4A O75164 1/20 0.35
KDM4B O94953 1/20 0.35
KDM5C P41229 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
TDP2 O95551 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1093963 0.78 IDO1 (0.44) IDO1TDO2CA1CA2CA9
SCHEMBL21091024 0.75 CASP6 (0.45) IDO1TDO2CASP6KDM4AKDM4B
SCHEMBL9959654 0.73 STAT3 (0.42) IDO1TDO2CA1CA2CA9
SCHEMBL15825758 0.72 IDO1 (0.42) IDO1TDO2CASP6KDM4AKDM4B
Formic Acid SCHEMBL19616984 0.72 STAT3 (0.41) IDO1TDO2CASP6CA1CA2
SCHEMBL4533718 0.71 CASP6 (0.45) IDO1TDO2CASP6KDM4AKDM4B
SCHEMBL8724464 0.71 KCNH2 (0.49) CA1CA2CA9CA12MAPK1
SCHEMBL14754342 0.71 CASP6 (0.48) IDO1TDO2CASP6KDM4AKDM4B
SCHEMBL14120534 0.70 CA2 (0.45) CA1CA2CA9CA12CA4
SCHEMBL2512862 0.70 KDM4A (0.49) IDO1TDO2CASP6KDM4AKDM4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3844150-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP claimed
EP-3844158-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP claimed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO claimed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO claimed
EP-3844150-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP disclosed
EP-3844158-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed